Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Raloxifene HCL Clear all

Conditions: Alzheimer Disease
Interventions: Raloxifene; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 55 Years to 90 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: Estradiol followed by progesterone, Raloxifene; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Osteoporosis
Interventions: lasofoxifene, raloxifene, Placebo; Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 48 Years to 75 Years · Female only
Enrollment: 540 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 72
States / cities: Albany, California • Berkeley, California • La Jolla, California + 49 more

Conditions: Osteoporosis, Postmenopausal, Osteoporosis
Interventions: denosumab, alendronate, raloxifene; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoporosis
Interventions: Teriparatide, Raloxifene; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 60 Years to 89 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Breast Cancer
Interventions: Raloxifene, Tamoxifen; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 35 Years and older · Female only
Enrollment: 19,747 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 492
States / cities: Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 369 more

Conditions: Brain Tumor
Interventions: Memantine, Raloxifene; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Cancer
Interventions: Lovaza 4gm oral, Raloxifene 60 Mg Oral Tablet, Raloxifene 30 Mg Oral Tablet, Lovaza 4gm & Raloxifene 30mg; Dietary Supplement · Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 266 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Endometriosis, Pelvic Pain
Interventions: Raloxifene; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Female only
Enrollment: 612 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoporosis, Post-Menopausal
Interventions: Raloxifene, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 55 Years to 85 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 2
States / cities: Indianapolis, Indiana • Omaha, Nebraska

Conditions: Osteoporosis
Interventions: BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 22
States / cities: Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more

Conditions: Cognition, Aging
Interventions: tamoxifen, raloxifene; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 65 Years and older · Female only
Enrollment: 1,498 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2008
U.S. locations: 127
States / cities: Phoenix, Arizona • Tucson, Arizona • Camp Pendleton, California + 102 more

Conditions: Osteoporosis, Postmenopausal
Interventions: teriparatide, raloxifene HCl, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Maywood, Illinois • Portland, Oregon

Conditions: Polycystic Ovarian Syndrome
Interventions: Raloxifene, Clomiphene; Drug
Lead sponsor: Bruce Lessey; Other
Eligibility: 18 Years to 36 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Alzheimer Disease
Interventions: raloxifene, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 60 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 4
States / cities: Santa Rosa, California • Stanford, California • Springfield, Illinois + 1 more

Conditions: Postmenopausal Osteoporosis
Interventions: teriparatide, aldrenodate, raloxifene; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 10
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 7 more

Conditions: Urinary Bladder Neoplasms
Interventions: Tamoxifen; Drug
Lead sponsor: Seth Lerner; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoporosis
Interventions: Raloxifene, Zoledronic acid, Placebo oral pills, Placebo intravenous (i.v.) infusion; Drug
Lead sponsor: Novartis; Industry
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Phoenix, Arizona • Buena Park, California • Washington D.C., District of Columbia + 12 more

Conditions: Breast Cancer
Interventions: Raloxifene - Usual, Raloxifene - Study; Drug
Lead sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair; Industry
Eligibility: 24 Years to 64 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Osteoporosis, Postmenopausal
Interventions: Arzoxifene, Raloxifene; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 5
States / cities: Gainesville, Georgia • Urbandale, Iowa • Billings, Montana + 2 more

Conditions: Cardiovascular Diseases, Breast Neoplasms
Interventions: raloxifene, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 55 Years and older · Female only
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Breast Cancer
Interventions: raloxifene, evaluation of cancer risk factors; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 23 Years to 47 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Stage IV Prostate Cancer
Interventions: bicalutamide, raloxifene, quality-of-life assessment; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Osteoporosis, Postmenopausal
Interventions: Raloxifene HCL, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: Up to 80 Years · Female only
Enrollment: 7,705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1999
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease

Estrogen Alternatives Study

Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

Comparative Antiresorptive Efficacy Discontinuation of Denosumab

Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?

Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain

Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention

The Safety and Effectiveness of Surgery With or Without Raloxifene for the Treatment of Pelvic Pain Caused by Endometriosis

Long Term Effects of Raloxifene Treatment on Bone Quality

Study Evaluating Changes In Mammographic Breast Density

Cognition in the Study of Tamoxifen and Raloxifene

Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis

Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome

Raloxifene for Women With Alzheimer's Disease

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment

Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis

Raloxifene Use for The Heart

Raloxifene in Preventing Breast Cancer in Premenopausal Women

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis